294 related articles for article (PubMed ID: 27771373)
1. Expression of cathepsins V and S in thymic epithelial tumors.
Kiuchi S; Tomaru U; Ishizu A; Imagawa M; Kiuchi T; Iwasaki S; Suzuki A; Otsuka N; Deguchi T; Shimizu T; Marukawa K; Matsuno Y; Kasahara M
Hum Pathol; 2017 Feb; 60():66-74. PubMed ID: 27771373
[TBL] [Abstract][Full Text] [Related]
2. Expression of cathepsins B, D and K in thymic epithelial tumours.
Yamaguchi N; Tomaru U; Kiuchi T; Ishizu A; Deguchi T; Otsuka N; Tanaka S; Marukawa K; Matsuno Y; Kitagawa M; Kasahara M
J Clin Pathol; 2021 Feb; 74(2):84-90. PubMed ID: 32467319
[TBL] [Abstract][Full Text] [Related]
3. Expression of proteasome subunit β5t in thymic epithelial tumors.
Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Marukawa K; Matsuno Y; Kasahara M
Am J Surg Pathol; 2011 Sep; 35(9):1296-304. PubMed ID: 21836487
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological significance of thymic epithelial markers expression in thymoma and thymic carcinoma.
Li H; Ren B; Yu S; Gao H; Sun PL
BMC Cancer; 2023 Feb; 23(1):161. PubMed ID: 36797681
[TBL] [Abstract][Full Text] [Related]
5. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
Chan JK; Tsang WY; Seneviratne S; Pau MY
Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of thymic epithelial markers CD205 (DEC205) and Foxn1 in thymic epithelial neoplasms.
Nonaka D; Henley JD; Chiriboga L; Yee H
Am J Surg Pathol; 2007 Jul; 31(7):1038-44. PubMed ID: 17592270
[TBL] [Abstract][Full Text] [Related]
7. Expression of thymoproteasome subunit β5t in type AB thymoma.
Yamada Y; Tomaru U; Ishizu A; Kiuchi T; Kasahara M; Matsuno Y
J Clin Pathol; 2014 Mar; 67(3):276-8. PubMed ID: 24293611
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms.
Kojika M; Ishii G; Yoshida J; Nishimura M; Hishida T; Ota SJ; Murata Y; Nagai K; Ochiai A
Mod Pathol; 2009 Oct; 22(10):1341-50. PubMed ID: 19648882
[TBL] [Abstract][Full Text] [Related]
9. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese Association for Research on the Thymus Database Study.
Omasa M; Date H; Sozu T; Sato T; Nagai K; Yokoi K; Okamoto T; Ikeda N; Tanaka F; Maniwa Y;
Cancer; 2015 Apr; 121(7):1008-16. PubMed ID: 25565590
[TBL] [Abstract][Full Text] [Related]
10. Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems.
Ma Y; Li Q; Cui W; Miao N; Liu X; Zhang W; Zhang C; Wang J
Diagn Pathol; 2012 Sep; 7():120. PubMed ID: 22974165
[TBL] [Abstract][Full Text] [Related]
11. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
12. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.
Weissferdt A; Fujimoto J; Kalhor N; Rodriguez J; Bassett R; Wistuba II; Moran CA
Mod Pathol; 2017 Jun; 30(6):826-833. PubMed ID: 28281549
[TBL] [Abstract][Full Text] [Related]
13. Glut-1 intensity and pattern of expression in thymic epithelial tumors are predictive of WHO subtypes.
Thomas de Montpréville V; Quilhot P; Chalabreysse L; De Muret A; Hofman V; Lantuéjoul S; Parrens M; Payan MJ; Rouquette I; Secq V; Girard N; Besse B; Marx A; Molina TJ
Pathol Res Pract; 2015 Dec; 211(12):996-1002. PubMed ID: 26534878
[TBL] [Abstract][Full Text] [Related]
14. Thymoma. Histologic subclassification is an independent prognostic factor.
Quintanilla-Martinez L; Wilkins EW; Choi N; Efird J; Hug E; Harris NL
Cancer; 1994 Jul; 74(2):606-17. PubMed ID: 8033040
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric analysis of lymphoid cells in thymic epithelial neoplasms.
Nakajima J; Takamoto S; Oka T; Tanaka M; Takeuchi E; Murakawa T
Eur J Cardiothorac Surg; 2000 Sep; 18(3):287-92. PubMed ID: 10973537
[TBL] [Abstract][Full Text] [Related]
16. Desmoglein 3 and p40 immunoreactivity in neoplastic and nonneoplastic thymus: a potential adjunct to help resolve selected diagnostic and staging problems.
Walts AE; Hiroshima K; Marchevsky AM
Ann Diagn Pathol; 2015 Aug; 19(4):216-20. PubMed ID: 25979154
[TBL] [Abstract][Full Text] [Related]
17. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis.
Weissferdt A; Moran CA
Am J Surg Pathol; 2011 Sep; 35(9):1305-10. PubMed ID: 21836478
[TBL] [Abstract][Full Text] [Related]
18. [The relationship between myasthenia gravis and the different pathological type of thymoma patients' operation and prognosis].
Zhang Y; Yu L; Jing Y; Ke J
Zhonghua Wai Ke Za Zhi; 2015 Aug; 53(8):612-6. PubMed ID: 26653963
[TBL] [Abstract][Full Text] [Related]
19. Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma. A clinicopathologic study of 22 cases.
Suster S; Moran CA
Am J Surg Pathol; 1996 Dec; 20(12):1469-80. PubMed ID: 8944040
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma.
Du MJ; Shen Q; Yin H; Rao Q; Zhou MX
Pathol Res Pract; 2016 Nov; 212(11):1048-1051. PubMed ID: 27688088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
